MS drug producers enjoy higher EPS
Published 27/10/2010 | 05:00
US drug firm Biogen Idec, which partners with Elan Pharmaceuticals on the sale of multiple sclerosis (MS) treatment Tysabri, said overall earnings per share rose to $1.05 from 95c in the last quarter but sales of the MS drug fell short of expectations.
Elan releases its third-quarter results today.
Fewer hit the shops in third quarter
FOOTFALL on high streets and in shopping centres across the Republic fell 1.7pc in the third quarter of the year compared to the same period in 2009, according to figures from Experian. The Central Statistics Office noted that retail sales rose in August, but footfall that month was down 5pc on July.
Firm to generate 50 new jobs in Galway
A US company that develops devices to allow hardware and software to talk to each other is creating 50 new jobs in Galway. Synchronoss, which is largely involved in the telecoms industry, is opening its international operations and research and development centre in the Parkmore business park. The new centre will run all of the company's non-US business. The firm has started recruiting software developers for its engineering, software and technology divisions.
Magners toasts UK sales for August
SALES of Magners cider in the UK rose 4pc year on year during August, according to the latest data from Nielsen Research. The growth was in line with the rest of the cider market in the UK. In Scotland, Magners sales were up 29pc, boosted by the route to market provided by its sister brand, Tennents lager. Outside of Scotland, however, volumes grew by only 1pc.
Ford speedy in US but slow in Europe
FORD yesterday reported its best third-quarter earnings in more than a decade, despite falling sales in Britain and Europe. The US car maker said that it was on track to gain market share in the US for the second straight year, though it was expecting that its market share in Europe, where it is the second-largest seller of cars behind Volkswagen, would continue to decline.